Loading...
Dear Readers,
In keeping with tradition, we feature our “Top 10” Journal Watch Gastroenterology summaries of 2011. This year, I have arranged these by the multiple areas of clinical gastroenterology that we review and that you practice.
So, what did we learn in 2011?
In hepatology, the data on telaprevir and its availability have resulted in a quantum shift in the treatment of hepatitis C infection.
For Barrett esophagus, we are increasingly questioning the value of surveillance — and now even screening — for this disease.
For irritable bowel syndrome and functional colon diseases, new effective treatments continue to emerge.
In inflammatory bowel disease, we are evolving to a new treatment endpoint beyond symptoms: mucosal healing.
In colonoscopy…